Priority Setting Stage

优先级设定阶段

• 批准号: 7515891
• 负责人: ALEC J DAVIDSON
• 金额: $ 1.49万
• 依托单位: MOREHOUSE SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-29 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7515891
• 关键词: Address; Adoption; Advisory Committees; African American; Anatomy; Animals; Applications Grants; Area; Arts; Atherosclerosis; Award; Benign Prostatic Hypertrophy; Biochemistry; Biology; Biomedical Research; Blood Vessels; Budgets; Cancer Biology; Cancer Center Planning Grant; Cardiovascular Pathology; Caring; Cellular biology; Chairperson; Circadian Rhythm Sleep Disorders; Clinic; Clinical; Clinical Trials Design; Collaborations; Committee Members; Communities; Community Health; Data; Development; Development Plans; Diagnosis; Disadvantaged; Division of Cancer Prevention; Doctor of Philosophy; Electronic Mail; Epidemiology; Ethnic group; Faculty; Functional disorder; Funding; Future; Genetic; Goals; Grant; Grant Review; Health; Healthcare; Hematology; Hormonal; Hospitals; Institutes; Institution; Knowledge; Laboratories; Lead; Life; Literature; Malignant Neoplasms; Malignant neoplasm of prostate; Medical; Medicine; Metastatic Neoplasm to the Bone; Minority; Mission; Modeling; Molecular; Molecular Biology; Names; Nanotechnology; National Cancer Institute; Neoplasm Metastasis; Neurobiology; Neurosciences; Office of Special Populations Research; Oncogenes; Other Minority; Outcome; Paper; Parents; Pathogenesis; Pattern; Phenotype; Physician Executives; Pilot Projects; Population; Prevention; Prevention Research; Prevention strategy; Preventive Medicine; Primary carcinoma of the liver cells; Principal Investigator; Process; Program Research Project Grants; Prostate; Prostate Cancer Prevention Trial; Public Health Schools; Publishing; Quantum Dots; Rattus; Request for Applications; Research; Research Personnel; Research Project Grants; Research Support; Scientific Advances and Accomplishments; Scientist; Score; Screening procedure; Services; Staging; Systems Biology; Therapeutic; Training; USA Georgia; United States National Institutes of Health; Universities; Urology; Western Asia Georgia; Work; Writing; base; beta-2 Microglobulin; cancer prevention; career; circadian pacemaker; disorder prevention; experience; health disparity; insight; interest; malignant breast neoplasm; medical schools; member; molecular imaging; novel therapeutics; oncology; professor; programs; racial and ethnic; racial difference; socioeconomics; therapeutic target

Priority-Setting Stage Pilot Project #1 (Drs. Davidson and Hsieh) is fully conceived, planned and staffed. Consequently this project will be implemented immediately upon funding. Pilot project #2 will be selected during Year 1 by a Priority-setting process described as follows. We have selected an Internal Advisory Committee comprised of 6 cancer investigators: The two Lead Pis plus 2 additional members from each institution: Morehouse School of Medicine Alec J. Davidson, PhD is an assistant professor in the Department of Anatomy and Neurobiology, and a member of the Neuroscience Institute and Circadian Rhythms and Sleep Disorders Program. Dr. Davidson has been pursuing research on the relationship between circadian clocks and cancer for 4 years, and is currently PI of an R21 grant from NCI to investigate this issue in a rat model of hepatocellular carcinoma. He is the MSM Lead-Pi of this grant application. Sandra Harris-Hooker, PhD is the Vice President and Associate Dean for Sponsored Research Administration at MSM, and the Director of the Minority Biomedical Research Support Program at Morehouse School of Medicine, a program dedicated to the development of future biomedical research scholars. With professional training in Cell Biology, and postgraduate emphasis in Cardiovascular Pathology, Dr. Harris- Hooker has worked in the area of vascular cell biology for over 20 years, studying endothelial dysfunctions involved in the pathogenesis of atherosclerosis. While her primary research area is vascular biology, she is also interested in ways by which to enhance the integration of basic, clinical and population-based research in order to address disparities in health. Dr. Harris-Hooker has been on the MSM faculty since 1983. Daniel Blumenthal, MD, MPH, is Chairman of the Department of Community Health and Preventive Medicine and Principal Investigator of the Morehouse School of Medicine Prevention Research Center (PRC). The mission of the PRC is to advance scientific knowledge in the field of prevention of disease in African American and other minority communities and to disseminate new information and strategies of prevention. Specifically, Dr. Blumenthal is PI of the Cancer Prevention and Control Research network within the PRC, whose mission it is to accelerate the adoption of evidence-based cancer prevention and control in minority communities. Winship Cancer Institute / Emory University Leland W. K. Chung, PhD, is an internationally recognized basic and translational prostate cancer scientist with substantial experience in coordinating multi-dimensional research projects and is currently the PI of a NCI funded prostate cancer program project grant (P01). Dr. Chung is a Professor of Urology, Biochemistry, and Hematology & Oncology, Director of the Molecular Urology and Therapeutics Program, and Director of the Prostate Cancer Program, WCI. Dr. Chung is the WCI Lead-Pi of this grant application. Dr. Chung's research has continuously received funding from the National Institutes of Health and National Cancer Institute over the past 30 years. He currently serves as the Principal Investigator of one NCI Program Projects entitled "Prostate cancer bone metastasis: biology and targeting" (Total: $6,016,114), a DoD Synergy Consortium targeting prostate cancer lethal phenotypes (Total: $9,999,999), two DoD Idea Awards grants entitled "Beta-2 microglobulin: a novel therapeutic target for the treatment of human prostate cancer bone metastasis" (Total: $573,750) and "Molecular imaging with quantum dots probing EMT and prostate cancer metastasis in live animals" (Total $573,750), and two industrial grants entitled "CNTO95: targeting prostate cancer bone metastasis" (Total $100,000), "Assessment of the co-targeting potential of prostate cancer metastasis" (Total $100,000); Dr. Chung currently serves as a Co-Investigator for an NCI sponsored Cancer Nanotechnology Center grant (Total: $7,239,413, PI: Shuming Nie), a P20 grant ($2,653,181, PI: Shuming Nie), and an R01 grant ($7,094,005, PI: Shuming Nie). Otis W. Brawley, MD, is professor of hematology, oncology, and medicine at the Emory University School of Medicine and Professor of Epidemiology at the Emory Rollins School of Public Health. He also serves as associate director of the Winship Cancer Institute at Emory University. In addition, Dr. Brawley is chief of hematology and oncology services and the medical director of the Georgia Cancer Coalition Center of Excellence at Grady Memorial Hospital. From 1995 to April 2001, he served as Assistant Director of the Office of Special Populations Research at the National Cancer Institute. Dr. Brawley was previously a senior in the Division of Cancer Prevention and Control at the National Cancer Institute where he was one of a group instrumental in the development and launching of the Prostate Cancer Prevention Trial. This 18,000-man trial is looking at screening and epidemiologic issues in prostate cancer as well as the potential for prevention of benign prostatic hyperplasia and prostate cancer. He also served as Chief of the NCI Intramural Prostate Cancer Clinic from 1993-1995. Dr. Brawley's research interests include the screening, epidemiology, diagnosis, prevention, and treatment of hormonal cancer. He has additional interests in the design of clinical trials, inclusion of minorities in trials and the availability of state-of-the-art health care to the socioeconomically disadvantaged. His work concerning racial differences in patterns of medical care and the similar outcomes among racial and ethnic groups when there is equal treatment is widely cited in medical and lay literature. He is the recipient of numerous awards and was recently named a Georgia Cancer Coalition Eminent Scholar. Jin-Tang Dong, PhD, is currently an Associate Professor of Oncology, Urology, and Genetics and Molecular Biology at Emory University School of Medicine. His research has primarily focused on two areas of cancer biology - cancer gene identification and molecular understanding of two cancer molecules identified in his laboratory (ATBF1 and KLF5). He has published more than 50 research papers and trained more than 20 people of varying levels in cancer biology. He participates regularly in grant reviewing for NIH and US Army breast cancer and prostate cancer programs. Selection of Pilot Project 2 During the first quarter of Year 1, Drs. Davidson and Chung will write a Request for Applications that will be distributed by broadcast email and fliers within WCI and MSM. Potential applicants will be asked to conceive of projects that are bidirectionally collaborative (benefiting both institutions), of high scientific value, and investigate an area of cancer biology that might yield insight regarding racial and ethnic health disparities (preferably prostate cancer). This includes the cellular, molecular or systems biology of cancers that are more diagnosed, or more deadly among minority populations. Successful applications must conform to the stipulations published in PAR-07-230, the announcement for this parent application. Any applications from trainees or faculty that have not yet successfully obtained any independent research funding will require a career development plan. The administrative core will collect and duplicate (or electronically distribute) the applications as needed for review. If applications are not responsive to the RFA they will be returned to applicants with that indication. After the application deadline, the IAC will be provided with the responsive applications, and asked to assign them priority ranks based on the criteria of: scientific merit, the strength of the collaboration (must be mutually beneficial), the potential of the project to generate publishable data and a competitive independent grant application, and the training potential for trainees and junior faculty. If the committee lacks the scientific expertise to evaluate applications for specific projects/programs, ad hoc reviewers either from within or outside the partnering institutions may be added to the IAC. Once scores have been assigned the IAC will then meet briefly to confer on their scores and decide which project to fund. If pilot project budgets are significantly less than the $120,000 maximum, the committee may choose to fund more than one project. In addition to reviewing and prioritizing new pilot projects/programs, the IAC will also evaluate ongoing pilot projects/programs and advise the Pis from both partnering components as to the general activities of the partnership and how they may contribute effectively to achieving high-priority goals and objectives. In exchange for their yearly service, committee members (but not the Lead Pis) and ad hoc reviewers (if necessary) will be compensated as consultants ($300 per year) as part of the budget for the administrative core.

确定优先级阶段 试点项目#1（Davidson 博士和 Hsieh 博士）经过充分构思、计划和人员配备。因此这 项目将在资金到位后立即实施。试点项目 #2 将在第一年由 优先级设置过程描述如下。 我们选择了一个由 6 名癌症研究人员组成的内部咨询委员会： 两位负责人 Pis 加上每个机构的 2 名额外成员： 莫尔豪斯医学院 Alec J. Davidson 博士是解剖学和神经生物学系的助理教授，也是 神经科学研究所和昼夜节律和睡眠障碍项目的成员。戴维森博士 四年来一直在研究生物钟与癌症之间的关系，并且正在 目前，他是 NCI 的 R21 资助的 PI，用于在肝细胞癌大鼠模型中研究这一问题。他是 本次拨款申请的 MSM Lead-Pi。 桑德拉·哈里斯·胡克博士是负责资助研究的副院长兼副院长 MSM 行政管理，莫尔豪斯少数族裔生物医学研究支持项目主任 医学院，一个致力于未来生物医学研究学者发展的项目。和 哈里斯博士在细胞生物学方面进行了专业培训，并在心血管病理学方面进行了研究生重点培训 Hooker 在血管细胞生物学领域工作了 20 多年，研究内皮功能障碍 参与动脉粥样硬化的发病机制。虽然她的主要研究领域是血管生物学，但她 也对如何加强基础、临床和基于人群的研究的整合感兴趣 以解决健康方面的差异。 Harris-Hooker 博士自 1983 年以来一直在 MSM 任教。 Daniel Blumenthal，医学博士、公共卫生硕士，社区健康和预防医学系主任 莫尔豪斯医学院预防研究中心（中国）首席研究员。这 PRC的使命是提高非裔美国人疾病预防领域的科学知识 和其他少数群体社区，并传播新的信息和预防战略。具体来说， Blumenthal 博士是中国癌症预防和控制研究网络的 PI，其使命是 旨在加速在少数群体社区采用循证癌症预防和控制方法。 温希普癌症研究所/埃默里大学 Leland W. K. Chung 博士是国际公认的基础和转化前列腺癌科学家 具有协调多维度研究项目的丰富经验，目前是 NCI 的 PI 资助前列腺癌计划项目拨款 (P01)。 Chung 博士是泌尿外科、生物化学和 血液学和肿瘤学，分子泌尿学和治疗项目主任，以及 前列腺癌计划，WCI。 Chung 博士是本次资助申请的 WCI Lead-Pi。 Chung博士的研究不断获得美国国立卫生研究院和美国国立卫生研究院的资助 美国国家癌症研究所过去 30 年。目前担任美国国家癌症研究所 (NCI) 的首席研究员 题为“前列腺癌骨转移：生物学和靶向”的计划项目（总计：6,016,114 美元），国防部 针对前列腺癌致死表型的协同联盟（总计：9,999,999 美元），两项国防部创意奖 题为“Beta-2微球蛋白：治疗人类前列腺癌的新型治疗靶点”的赠款 骨转移”（总计：573,750 美元）和“利用量子点探测 EMT 和前列腺的分子成像” 活动物中的癌症转移”（总计 573,750 美元），以及两项题为“CNTO95：靶向 前列腺癌骨转移”（总计100,000美元），“前列腺共靶向潜力的评估 癌症转移”（总计 100,000 美元）；Chung 博士目前担任 NCI 资助的一家机构的联合研究员 癌症纳米技术中心拨款（总计：7,239,413 美元，主要负责人：聂树明）、P20 拨款（2,653,181 美元，主要负责人： Shuming Nie），以及 R01 补助金（7,094,005 美元，PI：Shuming Nie）。 Otis W. Brawley，医学博士，埃默里大学医学院血液学、肿瘤学和医学教授 埃默里·罗林斯公共卫生学院医学和流行病学教授。他还担任 埃默里大学温希普癌症研究所副所长。此外，Brawley 博士是 血液学和肿瘤学服务以及佐治亚州癌症联盟中心的医学主任 格雷迪纪念医院的卓越表现。 1995年至2001年4月任特殊人群研究办公室助理主任 在国家癌症研究所。 Brawley 博士曾是癌症预防和治疗部门的高级职员 他是国家癌症研究所的控制小组之一，在该研究所的开发和研究中发挥了重要作用。 启动前列腺癌预防试验。这项 18,000 人参与的试验正在研究筛查和 前列腺癌的流行病学问题以及预防良性前列腺增生的潜力 和前列腺癌。 1993 年至 1995 年间，他还担任 NCI 壁内前列腺癌诊所主任。 Brawley 博士的研究兴趣包括筛查、流行病学、诊断、预防和 荷尔蒙癌症的治疗。他对临床试验的设计、少数族裔的纳入还有其他兴趣 试验以及向社会经济弱势群体提供最先进的医疗保健。他的作品 关于医疗保健模式的种族差异以及种族和民族之间的相似结果 医学和非专业文献中广泛引用了享有平等待遇的群体。他是接受者 荣获多项奖项，最近被评为乔治亚州癌症联盟杰出学者。 Jin-Tang Dong 博士，现任肿瘤学、泌尿学、遗传学和分子学副教授 埃默里大学医学院生物学。他的研究主要集中在癌症的两个领域 生物学-癌症基因鉴定和对他在他的研究中发现的两种癌症分子的分子理解 实验室（ATBF1 和 KLF5）。发表研究论文50余篇，培训20余名 癌症生物学水平不同的人。他定期参与 NIH 和美国陆军的拨款审查 乳腺癌和前列腺癌计划。 试点项目2的选择 在第一年的第一季度，博士。戴维森和钟将撰写一份申请请求，该请求将 通过 WCI 和 MSM 内的广播电子邮件和传单进行分发。潜在申请人将被要求怀孕 具有高度科学价值的双向合作项目（使两个机构受益），以及 研究癌症生物学领域，可能会产生有关种族和民族健康差异的见解 （最好是前列腺癌）。这包括癌症的细胞、分子或系统生物学 被诊断出来，或者在少数族裔中更加致命。成功的申请必须符合 PAR-07-230（本父申请的公告）中发布的规定。任何申请来自 尚未成功获得任何独立研究经费的学员或教师将需要 职业发展计划。管理核心将收集并复制（或以电子方式分发） 根据需要审查申请。如果申请没有对 RFA 作出回应，它们将被退回 具有该指示的申请人。 申请截止日期后，IAC 将收到响应申请，并要求 根据以下标准为他们分配优先级：科学价值、合作强度（必须是 互惠互利），该项目产生可发布数据的潜力和具有竞争力的独立 拨款申请，以及学员和初级教师的培训潜力。如果委员会缺乏科学依据 评估特定项目/计划的申请的专业知识，来自内部或外部的特设审查员 合作机构可能会被添加到 IAC 中。一旦分数被分配，IAC 将召开会议 简短地讨论他们的分数并决定资助哪个项目。如果试点项目预算明显减少 超过 120,000 美元的上限时，委员会可以选择资助多个项目。 除了审查新的试点项目/计划并确定其优先顺序外，IAC 还将评估正在进行的试点项目 项目/计划，并就项目/计划的一般活动向两个合作部门的PI提供建议 伙伴关系以及他们如何有效地促进实现高度优先的目标和目的。 作为每年服务的回报，委员会成员（但不是首席 Pi）和特设评审员（如果 必要）将作为顾问获得报酬（每年 300 美元），作为行政预算的一部分 核。